Search
Now showing items 1-2 of 2
Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries
(Sage, 2014)
Objective: Whilst dopaminergic dysfunction remains a necessary component involved in the pathogenesis of schizophrenia,
our current pharmacological armoury of dopamine antagonists does little to control the negative ...
A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia
(Elsevier, 2014)
Background: While antipsychotics are effective in the maintenance treatment of schizophrenia they have
safety and tolerability risks. We investigated whether a combination of omega-3 polyunsaturated fatty acids
(ω−3 ...